All lobbying filings

WILLIAMS AND JENSEN, PLLC

Lobbying for NOVOCURE INC. · Commercial stage oncology dedicated to advancement of TTF therapy to treat solid tumors.

Filing Registration

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Nov 20, 2025

Money reported

None

Registrations and no-activity reports carry no figure.

Client based in

New Hampshire

Official filing document

Lobbyists on this filing 5

LAURA M SIMMONS New on this filing

Previously held: Advisor, Office of Legislative Affairs, Dept of Homeland Security
ROBERT BUTORA New on this filing

Previously held: Health Policy Advisor, Senator Bill Cassidy; Senior Health Policy Advisor, Representative Leonard Lance, Health Legislative Assistant, Representative Michael Burgess
JOSHUA DAVID FENDRICK New on this filing

Previously held: Staff Assistant, Legislative Correspondent, and Legislative Aide, Sen. Gary C. Peters; Economic Policy Adviser, Rep. Josh Gottheimer; Economic Policy Adviser, Sen. Gary C. Peters
KURT SCHRADER Former member of Congress New on this filing

Previously held: Former Member of Congress
JEANNE HAGGERTY New on this filing

Previously held: Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Bills named in this filing 2

HR 5343
Ensuring Patient Access to Critical Breakthrough Products Act
S 1717
Ensuring Patient Access to Critical Breakthrough Products Act of 2025

Lobbying activity 2

Pharmacy

Lobbying for the breakthrough pathway bill (H.R. 5343, S. 1717), CMS reimbursement of medical devices generally, and FDA issues related to medical devices.

Veterans

Lobbying for the breakthrough pathway bill (H.R. 5343, S. 1717), CMS reimbursement of medical devices generally, and FDA issues related to medical devices.

Foreign interests disclosed 3

Section 7 of the LD-2: foreign entities that own part of the client, paid toward this lobbying, or stand to benefit from it.

NOVOCURE GMBH

Switzerland · 6340 Baar · owns 100% of the client · contributed $0.00
NOVOCURE LIMITED (OWNS 100% OF NOVOCURE LUXEMBOURG)

Jersey · St. Helier, JE2 4UF · owns 100% of the client · contributed $0.00
NOVOCURE LUXEMBOURG S.A.R.L. (OWNS 100% OF NOVOCURE GMBH)

Luxembourg · L-1273, Luxemborg · owns 100% of the client · contributed $0.00

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.